Britain and America have concluded a landmark trade agreement that will maintain zero levies on UK medicine shipments entering the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the NHS. This move ensures that tariffs on these vital goods will stay at zero for a timeframe of the next three years.
This agreement comes after earlier statements to hike duties on branded pharmaceutical imports, with figures mentioned reaching one hundred percent.
"This deal between the Britain bolsters the worldwide climate for innovative medicines and brings much-needed fairness to American-British drug exports," a release declared.
Economic Impact
Pharmaceuticals are one of the Britain's biggest goods shipped to the United States, which is clearly the biggest market for leading British pharmaceutical firms.
Statistics show that in the 12 months prior to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure made up nearly one-fifth of all goods exports in that span.
"This agreement secures employment, increases funding and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.
Detailed UK Commitments
The pact includes several key commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, repayments topped twenty percent.
Recent Tensions
The pact takes place against a protracted tension between the drug companies and the UK government over spending levels and approval rates.
These tensions were heightened by claims that US consumers were charged several times more for the identical medicines than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while major investments have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
